XENETIC BIOSCIENCES, INC. Management Fee Expense
XENETIC BIOSCIENCES, INC. (XBIO) reported Management Fee Expense of $4.85 thousand for the 12-month period ending 2013-08-31, per its 10-K filed 2013-11-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ManagementFeeExpense · last filed 2014-01-10
- XENETIC BIOSCIENCES, INC. management fee expense for the quarter ending 2012-11-30 was $7.75K.
- XENETIC BIOSCIENCES, INC. management fee expense for fiscal 2013 was $4.85K, a 75.48% decline from fiscal 2012.
- XENETIC BIOSCIENCES, INC. management fee expense for fiscal 2012 was $19.79K.
| Period end | Management Fee Expense 3 month | Management Fee Expense 12 month |
|---|---|---|
| 2013-08-31 | $4.85K 10-K · filed 2013-11-27 | |
| 2012-11-30 | $7.75K 10-Q · filed 2014-01-10 | |
| 2012-08-31 | $19.79K 10-K · filed 2013-11-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |